Regen BioPharma (RGBP) 10-Q 7 May 15 2015 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Mar. 31, 2015	1-May-15
Document And Entity Information
Entity Registrant Name	Regen BioPharma Inc
Entity Central Index Key	1589150
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-21
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		110,739,382
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2015

Balance_Sheet_Unaudited

Balance Sheet (Unaudited) (USD $)	Mar. 31, 2015	Sep. 30, 2014
CURRENT ASSETS
Cash	$521,974
Note Receivable	12,051	10,422
Accrued Interest Receivable	784	233
Total Current Assets	534,809	10,655
TOTAL ASSETS	534,809	10,655
Current Liabilities:
Bank Overdraft		6,137
Accounts payable	16,207	3,305
Notes Payable	133,751	120,169
Accrued payroll taxes	2,976	8,463
Accrued Interest	14,635	2,212
Accrued Rent	5,000
Accrued Payroll	7,501
Total Current Liabilities	180,070	140,286
Total Liabilities	180,070	140,286
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock, ($0.0001 par value) 500,000,000 shares authorized, 109,310,811 issued and outstanding as of March 31, 2015 and 51,907,917 shares issued and outstanding as of September 30, 2014	10,932	5,191
Series A Preferred, 90,000,000 authorized; 57,134,079 and outstanding as of March 31, 2015 and September 30, 2014 respectively	5,714
Series AA Preferred ($0.0001) par value 600,000 authorized and 30,000 and 0 outstanding as of March 31, 2015 and September 30, 2014 respectively	3
Additional Paid in capital	9,905,102	485,097
Contributed Capital	743,658	658,658
Retained Earnings (Deficit) accumulated during the development stage	-10,310,670	-1,278,577
Total Stockholders' Equity (Deficit)	354,739	-129,631
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$534,809	$10,655

Balance_Sheet_Parenthetical

Balance Sheet (Parenthetical) (USD $)	Mar. 31, 2015	Sep. 30, 2014
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	109,310,811	51,907,917
Common stock, shares outstanding	109,310,811	51,907,917
Series A Preferred stock, par value (in dollars per share)	$0.00	$0.00
Series A Preferred stock, shares authorized	90,000,000	90,000,000
Series A Preferred stock, shares issued	57,134,079
Series A Preferred stock, shares outstanding	57,134,079
Series AA Preferred stock, par value (in dollars per share)	$0.00	$0.00
Series AA Preferred stock, shares authorized	600,000	600,000
Series AA Preferred stock, shares issued	30,000	0
Series AA Preferred stock, shares outstanding	30,000	0

Statement_of_Operations_Unaudi

Statement of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
REVENUES
COST AND EXPENSES
Research and Development	22,969	8,042	25,206	13,867
General and Administrative	303,536	133,086	442,989	262,381
Consulting and Professional Fees	279,913	28,915	339,761	79,630
Rent	15,000		26,871
Total Costs and Expenses	621,419	170,043	834,828	355,878
OPERATING LOSS	-621,419	-170,043	-834,828	-355,878
OTHER INCOME & (EXPENSES)
Interest Income	291		551
Interest Expense	-9,188		-15,230
Capital contribution to parent		-16,158		-39,852
Loss on issuance of common shares for less than fair value	-8,179,432		-8,179,432
Preferred shares issued pursuant to contractual obligations	-3,154		-3,154
TOTAL OTHER INCOME (EXPENSE)	-8,191,483	-16,158	-8,197,265	-39,852
NET INCOME (LOSS)	($8,812,901)	($186,201)	($9,032,092)	($395,730)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	($0.12)	($0.00)	($0.10)	($0.01)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	71,986,230	51,910,000	93,139,424	51,552,253

Statement_of_Cash_Flows_Unaudi

Statement of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	($9,032,092)	($395,730)
Adjustments to reconcile net Income to net cash
Preferred Stock issued for Expenses	100
Preferred Stock issued for interest	891
Common Stock issued for expenses
Preferred Stock issued pursuant to contractual obligations	3,154
Common Stock issued to Consultants	226,177
Preferred Stock issued to Consultants	420
Increase (Decrease) in Accounts Payable	12,902	833
(Increase) Decrease in Notes Receivable	-1,629
(Increase) Decrease in Interest Receivable	-551
Increase (Decrease) in Bank Overdraft	-6,137
Increase (Decrease) in Accrued Expenses	19,437	6,764
Net Cash Provided by (Used in) Operating Activities	-8,777,329	-388,133
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash	0	300,000
Increase in Contributed Capital	85,000	95,000
Increase (Decrease) in Notes Payable	19,582
Increase in Convertible Notes Payable	882,686
Increase in issuance of stock below fair value	8,179,432
Increase in Additional Paid in Capital	132,603
Net Cash Provided by (Used in) Financing Activities	9,299,303	395,000
Net Increase (Decrease) in Cash	521,974	6,867
Cash at Beginning of Period		115,922
Cash at End of Period	521,974	122,789
Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt	882,686
Preferred Shares Issued for Debt	$6,000

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc, a Delaware corporation.
	The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials
	A. BASIS OF ACCOUNTING
	The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
	B. USE OF ESTIMATES
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	C. CASH EQUIVALENTS
	The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
	D. PROPERTY AND EQUIPMENT
	Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.
	E. FAIR VALUE OF FINANCIAL INSTRUMENTS
	Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:
	Level 1:  Quoted prices in active markets for identical assets or liabilities
	Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.
	Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	F. INCOME TAXES
	The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.
	The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of March 31, 2015 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.
	The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.
	Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
	G.  BASIC EARNINGS (LOSS) PER SHARE
	The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.
	Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.
	H. ADVERTISING
	Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the three months ended March 31, 2015 and $0 for the three months ended March 31, 2014.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	6 Months Ended
	Mar. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	NOTE 2.  RECENT ACCOUNTING PRONOUNCEMENTS
	In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.
	The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows.
	In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.
	In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award's grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.
	In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.
	On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.
	On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:
	The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.
	Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.
	While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position.
	On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position.
	A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies.  Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

Going_Concern

Going Concern	6 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 3. GOING CONCERN
	The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $ 10,310,670 during the period from April 24, 2012 (inception) through March 31, 2015. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. During the quarter ended March 31, 2015 the Company raised $775,000 through the issuance of convertible debt ( Note 4).

Notes_Payable_and_Convertible_

Related Party Transactions	6 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 7. RELATED PARTY TRANSACTIONS
	As of March 31, 2015 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $743,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090. The Company also utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month.
	As of March 31, 2015 Entest Biomedical Inc. is indebted to the Company in the amount of $12,052. $12,052 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.
	As of March 31, 2015 the Company is indebted to BMSN in the amount of $19,701. $19,701 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.
	As of March 31, 2015 the Company is indebted to David R. Koos in the amount of $50. $50 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.
	On March 6, 2015 the Company issued 2,060,214 of its common shares to David R. Koos, the Company’s Chairman and Chief Executive Officer, in satisfaction of $57,686 of convertible indebtedness.
	On March 17, 2015 the Company issued 2,060,214 of its shares of Series A Preferred stock to David R. Koos, the Company’s Chairman and Chief Executive Officer ,in accordance with the terms and conditions of a convertible note issued to David R. Koos by the Company.
	On March 9, 2015 the company issued 227,632 common shares of Regen to Todd Caven, the Company’s Chief Financial Officer, as consideration for consulting services performed by Caven prior to his employment with the Company.
	During the quarter ended March 31, 2015 the Company paid $9,000 and issued 1,000,000 shares of its Series A Preferred stock to Thomas Ichim, the Company’s Chief Scientific Officer, in consideration of the sale by Icim to the Company of all right, title, and interest in and to the certain invention (hereinafter “Invention”) entitled “Gene Silencing of the Brother of the Regulator of Imprinted Sites” for which a U.S. Patent Number, 8,263,571, issued by the United States Patent and Trademark Office on September 11, 2011.

Notes_Receivable

Related Party Transactions	6 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 7. RELATED PARTY TRANSACTIONS
	As of March 31, 2015 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $743,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090. The Company also utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month.
	As of March 31, 2015 Entest Biomedical Inc. is indebted to the Company in the amount of $12,052. $12,052 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.
	As of March 31, 2015 the Company is indebted to BMSN in the amount of $19,701. $19,701 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.
	As of March 31, 2015 the Company is indebted to David R. Koos in the amount of $50. $50 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.
	On March 6, 2015 the Company issued 2,060,214 of its common shares to David R. Koos, the Company’s Chairman and Chief Executive Officer, in satisfaction of $57,686 of convertible indebtedness.
	On March 17, 2015 the Company issued 2,060,214 of its shares of Series A Preferred stock to David R. Koos, the Company’s Chairman and Chief Executive Officer ,in accordance with the terms and conditions of a convertible note issued to David R. Koos by the Company.
	On March 9, 2015 the company issued 227,632 common shares of Regen to Todd Caven, the Company’s Chief Financial Officer, as consideration for consulting services performed by Caven prior to his employment with the Company.
	During the quarter ended March 31, 2015 the Company paid $9,000 and issued 1,000,000 shares of its Series A Preferred stock to Thomas Ichim, the Company’s Chief Scientific Officer, in consideration of the sale by Icim to the Company of all right, title, and interest in and to the certain invention (hereinafter “Invention”) entitled “Gene Silencing of the Brother of the Regulator of Imprinted Sites” for which a U.S. Patent Number, 8,263,571, issued by the United States Patent and Trademark Office on September 11, 2011.

Income_Taxes

Related Party Transactions	6 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 7. RELATED PARTY TRANSACTIONS
	As of March 31, 2015 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $743,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090. The Company also utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month.
	As of March 31, 2015 Entest Biomedical Inc. is indebted to the Company in the amount of $12,052. $12,052 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.
	As of March 31, 2015 the Company is indebted to BMSN in the amount of $19,701. $19,701 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.
	As of March 31, 2015 the Company is indebted to David R. Koos in the amount of $50. $50 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.
	On March 6, 2015 the Company issued 2,060,214 of its common shares to David R. Koos, the Company’s Chairman and Chief Executive Officer, in satisfaction of $57,686 of convertible indebtedness.
	On March 17, 2015 the Company issued 2,060,214 of its shares of Series A Preferred stock to David R. Koos, the Company’s Chairman and Chief Executive Officer ,in accordance with the terms and conditions of a convertible note issued to David R. Koos by the Company.
	On March 9, 2015 the company issued 227,632 common shares of Regen to Todd Caven, the Company’s Chief Financial Officer, as consideration for consulting services performed by Caven prior to his employment with the Company.
	During the quarter ended March 31, 2015 the Company paid $9,000 and issued 1,000,000 shares of its Series A Preferred stock to Thomas Ichim, the Company’s Chief Scientific Officer, in consideration of the sale by Icim to the Company of all right, title, and interest in and to the certain invention (hereinafter “Invention”) entitled “Gene Silencing of the Brother of the Regulator of Imprinted Sites” for which a U.S. Patent Number, 8,263,571, issued by the United States Patent and Trademark Office on September 11, 2011.

Related_Party_Transactions

Related Party Transactions	6 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 7. RELATED PARTY TRANSACTIONS
	As of March 31, 2015 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $743,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090. The Company also utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month.
	As of March 31, 2015 Entest Biomedical Inc. is indebted to the Company in the amount of $12,052. $12,052 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.
	As of March 31, 2015 the Company is indebted to BMSN in the amount of $19,701. $19,701 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.
	As of March 31, 2015 the Company is indebted to David R. Koos in the amount of $50. $50 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.
	On March 6, 2015 the Company issued 2,060,214 of its common shares to David R. Koos, the Company’s Chairman and Chief Executive Officer, in satisfaction of $57,686 of convertible indebtedness.
	On March 17, 2015 the Company issued 2,060,214 of its shares of Series A Preferred stock to David R. Koos, the Company’s Chairman and Chief Executive Officer ,in accordance with the terms and conditions of a convertible note issued to David R. Koos by the Company.
	On March 9, 2015 the company issued 227,632 common shares of Regen to Todd Caven, the Company’s Chief Financial Officer, as consideration for consulting services performed by Caven prior to his employment with the Company.
	During the quarter ended March 31, 2015 the Company paid $9,000 and issued 1,000,000 shares of its Series A Preferred stock to Thomas Ichim, the Company’s Chief Scientific Officer, in consideration of the sale by Icim to the Company of all right, title, and interest in and to the certain invention (hereinafter “Invention”) entitled “Gene Silencing of the Brother of the Regulator of Imprinted Sites” for which a U.S. Patent Number, 8,263,571, issued by the United States Patent and Trademark Office on September 11, 2011.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 8. COMMITMENTS AND CONTINGENCIES
	The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month.
	On March 20, 2015 Regen Biopharma, Inc. agreed to sublease 199 square feet of laboratory space located at 5310 Eastgate Mall, San Diego, CA 92121 from Human BioMolecular Research Institute (“Sublease Agreement”). Pursuant to the terms of the Sublease Agreement Regen Biopharma, Inc. will pay rent of $400 per month to Human BioMolecular Research Institute (“HBRI”) . The term of the sublease shall be from March 9, 2015 to September 8, 2015 (a period of 6 months) and will automatically renew thereafter for the same 6 month term unless written notice is received by HBRI within 60 days prior to renewal.
	On March 20, 2015 Regen Biopharma, Inc entered into a Research Agreement with HBRI wherein HBRI agreed to provide a variety of professional, scientific and technical services for the proper conduct of research by Regen Biopharma, Inc. and also to make available certain research equipment to Regen Biopharma, Inc. The term of the agreement shall be from March 9, 2015 to September 8, 2015 (a period of 6 months) and will automatically renew thereafter for the same 6 month term unless written notice is received by HBRI within 60 days prior to renewal. As consideration Regen Biopharma, Inc shall pay a monthly fee of $2,700 to HBRI over the term of the agreement.

Stockholders_Equity

Stockholders Equity	6 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders Equity	NOTE 9. STOCKHOLDERS' EQUITY
	The stockholders' equity section of the Company contains the following classes of capital stock as March 31, 2015:
	Common stock, $ 0.0001 par value; 500,000,000 shares authorized: 109,310,811 shares issued and outstanding.
	With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).
	On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation.
	Preferred Stock, $0.0001 par value, 100,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 30,000 shares issued and outstanding as of March 31, 2015 and 90,000,000 is designated Series A Preferred Stock of which 57,134, 079 shares are outstanding as of March 31, 2015.
	The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired.
	Series AA Preferred Stock
	On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”).
	The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders.
	Series A Preferred Stock
	On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series A Preferred Stock" (hereinafter referred to as "Series A Preferred Stock").
	The Board of Directors of the Company have authorized 90,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders.
	Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock.
	Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them.
	If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.

Stock_Dividend

Stock Dividend	6 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Stock Dividend	NOTE 10. STOCK DIVIDEND
	During the quarter ended March 31, 2015 a stock dividend of 10,395,217 Series A Preferred shares was paid to the Company’s common shareholders of record as of March 10, 2015. Common shareholders received one share of Series A Preferred Stock for every 10 shares of Regen Biopharma, Inc. common Stock owned as of the Record Date.

Stock_Transactions

Stock Transactions	6 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Stock Transactions	NOTE 11. STOCK TRANSACTIONS
	Common Stock:
	On February 13, 2015 the Company issued 9,000,000 of its common shares to David R. Koos, the Company’s Chairman and Chief Executive Officer, as a Restricted stock Award.
	On February 13, 2015 the Company issued 7,500,000 of its common shares to Todd Caven, the Company’s Chief Financial Officer, as a Restricted stock Award.
	On February 13, 2015 the Company issued 6,000,000 of its common shares to Thomas ichim, the Company’s Chief Scientific Officer and a member of the Board of Directors, as a Restricted stock Award.
	On March 6 , 2015 19,932,520 Common Shares were issued in satisfaction of $557,686 of convertible indebtedness and $890 of accrued interest on Convertible Notes.
	On March 6, 2015 the Company issued 500,000 of its common shares with a fair value of $140,000 as consideration for consulting services rendered.
	On March 6, 2015 the Company issued 227,632 of its common shares with a fair value of $ 63,737 to the Company’s Chief Financial Officer as consideration for consulting services rendered prior to his employment with the Company.
	Between March 9, 2015 and March 26, 2015 11,606,742 Common Shares were issued in satisfaction of $325,000 of convertible indebtedness.
	Series A Preferred Stock:
	On March 11, 2015 a stock dividend of 10,395,217 Series A Preferred shares was paid to the Company’s common shareholders of record as of March 10, 2015. Common shareholders received one share of Series A Preferred Stock for every 10 shares of Regen Biopharma, Inc. common Stock owned as of the Record Date.
	On March 17, 2015 the Company issued 26,181,719 shares of its Series A Preferred Stock in accordance with the terms and conditions of convertible notes issued.
	On March 17, 2015 the Company issued 2,500,000 shares of its Series A Preferred Stock to David R. Koos, the Company’s Chairman and Chief Executive Officer, as a Restricted Stock Award
	On March 17, 2015 the Company issued 2,500,000 shares of its Series A Preferred Stock to Todd Caven, the Company’s Chief Financial Officer, as a Restricted Stock Award
	On March 17, 2015 the Company issued 2,500,000 shares of its Series A Preferred Stock to Thomas Ichim, the Company’s Chief Scientific Officer, as a Restricted Stock Award
	On March 17, 2015 the Company issued 1,000,000 shares of its Series A Preferred Stock to Thomas Ichim, the Company’s Chief Scientific Officer, as partial consideration for the sale to the company by Ichim of all right, title, and interest in and to the certain invention (hereinafter “Invention”) entitled “Gene Silencing of the Brother of the Regulator of Imprinted Sites” for which a U.S. Patent Number, 8,263,571, issued by the United States Patent and Trademark Office on September 11, 2011
	On March 17, 2015 the Company issued 2,500,000 shares of its Series A Preferred Stock to an employee as a Restricted Stock Award.
	On March 17, 2015 the Company issued 4,200,000 shares of its Series A Preferred Stock to consultants for services.
	Series AA Preferred Stock:
	On February 13, 2015 the Company issued 10,000 shares of its Series AA Preferred Stock to Bio Matrix Scientific Group, Inc. (“BMSN”) in satisfaction of $2,000 of indebtedness owed by the company to BMSN.
	On March 23, 2015 the Company issued 20,000 shares of its Series AA Preferred Stock to Bio Matrix Scientific Group, Inc. (“BMSN”) in satisfaction of $4,000 of indebtedness owed by the company to BMSN.

Subsequent_Events

Subsequent Events	6 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	NOTE 12. SUBSEQUENT EVENTS
	On April 6, 2015 Regen issued a $40,000 face value Convertible Promissory Note ( “Note”) to joint individual investors (“Lender”) for consideration of $40,000. The Note becomes due and payable at the demand of the Lender at any time after March 6, 2016 and bears simple interest at 10% per annum payable quarterly at the demand of the Lender.
	All or part of the principal and accrued but unpaid interest is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent the lower of (1) a 65% discount to the lowest Trading Price (as defined below) for the Common Shares during the thirty (30) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the conversion date. “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. “Trading Day” shall mean any day on which the Common Shares are tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Shares are then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lender’s securities.
	Or
	(2) $0.03 per share
	Principal and interest may be prepaid in part or in full by Regen on not less than three Trading Days prior written notice to the Lender.
	Upon expiration of the six month holding specified in Rule 144(d) promulgated under the Securities Act of 1933, Regen , at the request of the Lender, shale remove sale restrictions on one sixth (1/6) of the shares that resulted from conversions made through the issuance of this Note , each month, for a period of six months, with all restrictions being removed by the Company by the expiration of the six month subsequent to expiration of the aforementioned Rule 144 holding period.
	If the Lender converts principal into Common Stock of Regen on or prior to 180 days from the issuance of the Note the Lender shall receive one share of Preferred Series “A” Stock of the Company for each share of Common Stock received through conversion.
	On April 14, 2015 1,428,571 Common Shares of Regen were issued in satisfaction of the abovementioned convertible note.
	On April 14, 2015 the Company issued 1,428,571 shares of its Series A Preferred Stock in accordance with the terms and conditions of abovementioned convertible note.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING
	The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
USE OF ESTIMATES	B. USE OF ESTIMATES
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
CASH EQUIVALENTS	C. CASH EQUIVALENTS
	The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
D. PROPERTY AND EQUIPMENT	D. PROPERTY AND EQUIPMENT
	Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.
FAIR VALUE OF FINANCIAL INSTRUMENTS	E. FAIR VALUE OF FINANCIAL INSTRUMENTS
	Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:
	Level 1:  Quoted prices in active markets for identical assets or liabilities
	Level 2:  Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.
	Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
INCOME TAXES	F. INCOME TAXES
	The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.
	The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of March 31, 2015 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.
	The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established.
	Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	G.  BASIC EARNINGS (LOSS) PER SHARE
	The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.
	Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.
ADVERTISING	H. ADVERTISING
	Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the three months ended March 31, 2015 and $0 for the three months ended March 31, 2014.

Notes_Payable_and_Convertible_1

Notes Payable and Convertible Notes Payable (Tables)	6 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Notes Payable		31-Mar-15		September 30,
				2014
	Bio Matrix Scientific Group, Inc. (Note 7)		19,701		90,000
	David Koos ( Notes7)		50		30,168
	Bio Technology Partners Business Trust		114,000		0
	Notes payable	$	133,751	$	120,168

Notes_Receivable_Tables

Notes Receivable (Tables)	6 Months Ended
	Mar. 31, 2015
Receivables [Abstract]
Notes Receivable		31-Mar-15		September 30,
				2014
	Entest Biomedical, Inc. (Note 7)	$	12,051	$	10,422
	Notes Receivable	$	12,051	$	10,422

Income_Taxes_Tables

Income Taxes (Tables)	6 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Deferred tax assets	Deferred tax assets:
	Net operating tax carry forwards	$	3,505,628
	Other		-0-
	Gross deferred tax assets		3,505,628
	Valuation allowance		(3,505,628	)
	Net deferred tax assets	$	-0-

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Advertising expenses	$0	$0

Going_Concern_Details_Narrativ

Going Concern (Details Narrative) (USD $)	35 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss since inception	($10,310,670)

Notes_Payable_and_Convertible_2

Notes Payable and Convertible Notes Payable - Notes Payable (Details) (USD $)	Mar. 31, 2015	Sep. 30, 2014
Debt Disclosure [Abstract]
Bio Matrix Scientific Group, Inc. (Note 7)	$19,701	$90,000
David Koos ( Notes7)	50	30,168
Bio Technology Partners Business Trust	114,000	0
Notes payable	$133,751	$120,168

Notes_Payable_and_Convertible_3

Notes Payable and Convertible Notes Payable (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Face value of convertible notes issued	$882,686
Cash consideration for issued notes	775,000
Satisfaction of existing indebtedness	107,686
Common shares issued upon conversion of notes payable	31,539,262
Series A preferred shares issued upon conversion of notes payable	31,538,862
Derivative liability	$2,368,685

Notes_Receivable_Notes_Receiva

Notes Receivable - Notes Receivable (Details) (USD $)	Mar. 31, 2015	Sep. 30, 2014
Receivables [Abstract]
Entest Biomedical, Inc. (Note 7)	$12,051	$10,422
Note Receivable	$12,051	$10,422

Notes_Receivable_Details_Narra

Notes Receivable (Details Narrative) (USD $)	Mar. 31, 2015	Sep. 30, 2014
Receivables [Abstract]
Entest Biomedical note receivable	$12,051	$10,422
Interest rate on note receivable	10.00%

Income_Taxes_Deferred_tax_asse

Income Taxes - Deferred tax assets (Details) (USD $)	Mar. 31, 2015
Deferred tax assets:
Net operating tax carry forwards	$3,505,628
Other
Gross deferred tax assets	3,505,628
Valuation allowance	-3,505,628
Net deferred tax assets

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Deferred Tax Asset	$3,505,628
Net operating loss carry forwards	$10,310,670
Federal corporate rate	34.00%

Related_Party_Transactions_Det

Related Party Transactions (Details Narrative) (USD $)	3 Months Ended	35 Months Ended
	Mar. 31, 2015	Mar. 31, 2015	Mar. 17, 2015	Mar. 09, 2015	Mar. 06, 2015	Sep. 30, 2014
Related Party Transactions [Abstract]
Capital contributions from related party		$743,658
Common shares issued to BMSN		50,010,000
Value of shares issued to BMSN		20,090
Monthly rent payable to Entest	5,000
Amount due from related party (ENTB)	12,052	12,052
Amount payable to related party (BMSN)	19,701	19,701				90,000
Amount due to company CEO	50	50
Common shares issued to ceo in satisfaction of convertible debt					2,060,214
Amount of debt converted					57,686
Series A Preferred stock issued to ceo			2,060,214
Common shares issued to cfo for consulting services				227,632
Cash paid to cso for intangible asset	$9,000
Shares issued to cso	1,000,000

Commitments_and_Contingencies_

Commitments and Contingencies (Details Narrative) (USD $)	Mar. 20, 2015
Commitments and Contingencies Disclosure [Abstract]
Monthly sublease fee to HBRI	$400
Monthly research agreement fee	$2,700

Stockholders_Equity_Details_Na

Stockholders Equity (Details Narrative) (USD $)	Mar. 31, 2015	Sep. 30, 2014
Equity [Abstract]
Common stock, Par value	$0.00	$0.00
Common stock, authorized	500,000,000	500,000,000
Common stock issued and outstanding	109,310,811	51,907,917
Preferred stock, par value	$0.00
Preferred stock, authorized	100,000,000
Series AA Preferred stock, shares authorized	600,000	600,000
Series AA Preferred stock, shares issued and outstanding	30,000	0
Series A Preferred stock, shares authorized	90,000,000	90,000,000
Series A Preferred stock, shares issued and outstanding	57,134,079
Series A Preferred stock, par value	$0.00	$0.00
Series AA Preferred stock, par value	$0.00	$0.00

Stock_Dividend_Details_Narrati

Stock Dividend (Details Narrative)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Stock dividend paid	10,395,217

Stock_Transactions_Details_Nar

Stock Transactions (Details Narrative) (USD $)	1 Months Ended
	Mar. 26, 2015	Mar. 23, 2015	Mar. 17, 2015	Mar. 06, 2015	Feb. 13, 2015
Notes to Financial Statements
Common stock issued to CEO as Restricted Stock Award					9,000,000
Common stock issued to CFO as Restricted Stock Award					7,500,000
Common stock issued to CSO as Restricted Stock Award					6,000,000
Common shares issued for conversion of debt				19,932,520
Amount of debt converted				$557,686
Common shares issued for consulting services				500,000
Value of consulting services				140,000
Fair value of CFO consulting services				63,737
Total common shares issued for debt conversions	11,606,742
Total debt converted	325,000
Series A preferred stock issued for convertible debt			26,181,719
Series A stock issued to CEO as Restricted Stock Award			2,500,000
Series A stock issued to CFO as Restricted Stock Award			2,500,000
Series A stock issued to CSO as Restricted Stock Award			2,500,000
Series A stock issued to employee as Restricted Stock Award			2,500,000
Series A stock issued for consulting services			4,200,000
Series AA preferred stock issued for debt		20,000			10,000
Amount of debt satisfied		$4,000			$2,000

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	Apr. 14, 2015	Apr. 06, 2015
Subsequent Events [Abstract]
Convertible Promissory note issued		$40,000
Common stock issued for April 6 convertible note	1,428,571
Series A shares issued for April 6 convertible note	1,428,571